BIOGEN INC. FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $9.9B |
| Gross margin | 75.7% |
| Operating income | — not reported |
| Net income | $1.3B |
| Diluted EPS | $8.79 |
| Cash & equivalents | — not reported |
| Total assets | $29.4B |
| Long-term debt | $6.3B |
Key takeaway
Biogen closed multiple business-development deals in 2025, including the Alcyone acquisition and licensing agreements with Dayra, Vanqua, City Therapeutics and Stoke, each requiring upfront cash payments recorded as R&D expense.
🔒 4 more takeaways in the full analysis
Beneath the surface
The Royalty Pharma funding arrangement provided $200 million in 2025 (with up to $50 million more in 2026) that was recorded as a reduction to R&D expense rather than as debt or equity, effectively flattering reported R&D costs and net income.
🔒 4 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 8 more findings — plus insider trades, activist stakes, and 8-K events for BIIB.
Read the full analysis free Free account · 5 full analyses included · no card required